• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Hematology/Oncology Classics

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

byDeepti Shroff Karhade
June 30, 2022
in Hematology/Oncology Classics, The Classics
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. Administrators overseeing the national liver transplantation network approved new policy to standardize radiologic imaging criteria for patients with hepatocellular carcinoma (HCC) to qualify for exemption points. Radiologists in US liver transplantation centers asked to implement this policy.

2. This new policy recommends various technical and procedural standards for CT and MR imaging, diagnosis, and classification criteria of HCC. It also seeks to standardize reporting requirements of HCC assessment to transplant networks.

Original Date of Publication: February 2013

Study Rundown: In the United States today, there are approximately three times more patients awaiting liver transplants than those who actually receive a liver. In order to distribute livers to patients determined to be most in need, the Organ Procurement and Transplantation Network (OPTN) and United Network for Organ Sharing (UNOS) set policy in 2002 giving priority to patients most ill and most likely to benefit from transplantation. Patients with early stage HCC have very good prognosis if able to receive a transplant. Therefore, the 2002 OPTN policy was designed to be favorable to patients reported to have early stage HCC and gave exemption points to early-stage HCC patients moving them higher on the Model for End-Stage Liver Disease (MELD) scale of 6 (less ill) to 40 (gravely ill) used to guide which patients received livers. However, the 2002 OPTN/UNOS policy had little structure guiding how HCCs should be diagnosed and reported to the networks. Assessment of UNOS data in 2006 indicated radiologic and pathologic assessment of HCCs only matched for 44.1% of cases. This prompted interest in creating new policy that would enhance imaging accuracy, diagnosis, and reporting of HCC to the transplant networks in order to better distribute liver transplants to HCC patients most likely to benefit. The new liver allocation policy was approved by OPTN/UNOS in 2011. This policy outlines various technological and procedural standards for imaging, classifying, and reporting HCC studies to OPTN. Under the OPTN classification system there are two broad categories of classes, Class 0 and class 5. Class 0 imaging studies are not of sufficient standard to qualify for exception points, and Class 5 studies may qualify for exemption points. Based on characteristics of the tumor upon imaging, the HCC may be reported as Class 5A, 5A-g, 5B, 5T, or 5X, each of which may change the number of exemption points a patient may receive and change their likelihood of receiving a liver transplant.

Click to read the study in Radiology

In-Depth [policy update]: To increase the likelihood that patients with early-stage HCC receive a liver transplant, as their post transplant survival rates are high but current severity of illness is relatively low, these patients are given exception points on OPTN/UNOS transplant lists. New OPTN/UNOS recommendations aim to verify that patients receiving exemption points do indeed have early-stage HCC and outline technological and procedural standards to be met for imaging studies. Such standards include type of CT or MR scanner and contrast to be used. If a liver imaging study reported to OPTN/UNOS does not meet these recommended specifications, it is assigned as Class 0 and no exemption points can be applied. For Class 0 studies it is recommended that the imaging study be redone meeting stated standards. If the imaging study meets these standards, it is Class 5 and further categorized. If the nodule in question is 1-2 cm in diameter and meets qualitative imaging criteria for HCC it is Class 5A. If a nodule appears arterially hyperenhanced, is at least 10 mm in diameter at diagnosis, and has grown 50+% in diameter over a period of 6 months or less is Class 5A-g. A patient having 2-3 Class 5A or 5A-g lesions would qualify them for exemption points. Arterially enhanced 2-5 cm nodules with at least one of two venous phase features (washout or pseudocapsule), or arterially enhanced 2-5 cm nodules displaying 50+% growth in diameter over a period of 6 months or less is Class 5B. Exemption points may be individually requested for Class 5B nodules. Arterially enhanced 5+cm nodules with at least one of two venous features, is Class 5X and typically not eligible for liver transplant. Nodules categorized as Class 5 or confirmed as HCC upon biopsy which were subsequently treated are Class 5T. Class 5T nodules may receive exemption points based on the prior treatment and size. Reports to OPTN seeking exemption points for HCC must use the described classification system. A summary at the end of the report listing number, location, and size of nodules is strongly encouraged.

RELATED REPORTS

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

PECARN Prediction rules for children at a low risk of clinically-important traumatic brain injury [Classics Series]

Study reports improvement in pediatric liver transplant outcomes over past decades

Wald C, Russo M, Heimbach J, Hussain H, Pomfret E, Bruix J. New OPTN/UNOS Policy for Liver Transplant Allocation: Standardization of Liver Imaging, Diagnosis, Classification, and Reporting of Hepatocellular Carcinoma. Radiology. 2013;266(2):376-382.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CT scanhepatocellular carcinomaliver transplantMagnetic Resonance Imaging (MRI)
Previous Post

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

Next Post

Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination

RelatedReports

Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Pediatrics Classics

PECARN Prediction rules for children at a low risk of clinically-important traumatic brain injury [Classics Series]

September 22, 2022
Chronic Disease

Study reports improvement in pediatric liver transplant outcomes over past decades

September 19, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Neurology Classics

Thrombolysis harmful in acute ischemic strokes with large area of parenchymal hypoattenuation [Classics Series]

September 7, 2022
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination

Relugolix combination therapy is efficacious for endometriosis-associated pain

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options